Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acet...(ently-completed clinical trials of Aceta...),Health

Date:1/11/2008

ently-completed clinical trials of Acetavance may vary from the company's initial analyses, and the FDA may not agree with Cadence's interpretation of such results; additional ongoing or planned clinical trials of Acetavance conducted by the company may produce negative or inconclusive results, or may be inconsistent with clinical trials conducted by its licensors or others, and the company may decide, or the FDA may require Cadence, to conduct additional clinical trials or to modify the company's ongoing clinical trials; Cadence may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit the company's ability to obtain regulatory approval; the third parties upon whom Cadence relies to conduct its clinical trials and manufacture its product candidates may not perform as expected; Cadence's product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of Acetavance or Omigard could delay or prevent regulatory approval or commercialization, or could result in recalls or product liability claims; the market potential for pain, fever, local catheter site infections and other target markets may be less than anticipated, and the company may be unable to successfully compete in these markets; the company will need to obtain substantial additional funding to complete its product development plans and may not be able to raise sufficient capital when needed; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
3. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
4. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
5. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
6. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
7. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
8. Cumberland Pharmaceuticals Announces Appointments
9. Pacira Pharmaceuticals Names David M. Stack CEO and President
10. Panacea Pharmaceuticals Initiates GMP Manufacturing of Prostate Cancer Diagnostic Test Kits
11. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology